Artificial intelligence (AI) software developer Oxipit closed on $4.9 million (4.5 million euros) in funding with aims to offer its products in new regions, particularly the U.K.
Oxipit offers several AI applications that have received the CE Mark in Europe, namely ChestLink and Oxipit Quality, software applications designed to provide quality control for chest x-rays, musculoskeletal x-rays, CT, and mammography medical images.
The funding round was led by Taiwania Capital, Practica Capital, and Coinvest Capital. Angel investors also participated in the round, the company reported.
